Goldman Sachs Group Inc. Acquires 69,733 Shares of Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX)

Goldman Sachs Group Inc. lifted its holdings in shares of Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) by 5.9% in the fourth quarter, according to its most recent filing with the SEC. The firm owned 1,256,861 shares of the company’s stock after acquiring an additional 69,733 shares during the period. Goldman Sachs Group Inc. owned approximately 1.85% of Amylyx Pharmaceuticals worth $18,501,000 as of its most recent filing with the SEC.

Several other institutional investors have also made changes to their positions in the business. Vanguard Group Inc. raised its position in Amylyx Pharmaceuticals by 2.5% in the third quarter. Vanguard Group Inc. now owns 5,050,080 shares of the company’s stock worth $92,467,000 after purchasing an additional 124,188 shares in the last quarter. Adage Capital Partners GP L.L.C. raised its holdings in shares of Amylyx Pharmaceuticals by 121.3% in the 3rd quarter. Adage Capital Partners GP L.L.C. now owns 1,700,200 shares of the company’s stock worth $31,131,000 after buying an additional 932,000 shares in the last quarter. Franklin Resources Inc. lifted its position in shares of Amylyx Pharmaceuticals by 114.4% during the 4th quarter. Franklin Resources Inc. now owns 1,325,001 shares of the company’s stock worth $19,504,000 after buying an additional 707,134 shares during the period. Hudson Bay Capital Management LP boosted its stake in Amylyx Pharmaceuticals by 134.5% in the 3rd quarter. Hudson Bay Capital Management LP now owns 682,223 shares of the company’s stock valued at $12,492,000 after buying an additional 391,323 shares in the last quarter. Finally, Charles Schwab Investment Management Inc. grew its position in Amylyx Pharmaceuticals by 5.9% in the fourth quarter. Charles Schwab Investment Management Inc. now owns 387,620 shares of the company’s stock valued at $5,706,000 after acquiring an additional 21,758 shares during the period. 95.84% of the stock is currently owned by institutional investors and hedge funds.

Amylyx Pharmaceuticals Price Performance

AMLX opened at $1.83 on Thursday. The stock has a market capitalization of $124.46 million, a P/E ratio of -1.71 and a beta of -0.68. The company’s 50 day simple moving average is $1.81 and its 200-day simple moving average is $8.33. Amylyx Pharmaceuticals, Inc. has a one year low of $1.58 and a one year high of $25.48.

Amylyx Pharmaceuticals (NASDAQ:AMLX) last announced its quarterly earnings data on Friday, May 10th. The company reported ($0.46) EPS for the quarter, missing analysts’ consensus estimates of $0.24 by ($0.70). The firm had revenue of $88.64 million during the quarter, compared to the consensus estimate of $113.26 million. Amylyx Pharmaceuticals had a negative net margin of 17.86% and a positive return on equity of 4.14%. During the same quarter in the previous year, the business posted $0.02 earnings per share. As a group, analysts anticipate that Amylyx Pharmaceuticals, Inc. will post -1.36 EPS for the current year.

Analyst Upgrades and Downgrades

AMLX has been the topic of several recent analyst reports. The Goldman Sachs Group restated a “neutral” rating on shares of Amylyx Pharmaceuticals in a research note on Friday, March 8th. SVB Leerink lowered shares of Amylyx Pharmaceuticals from an “outperform” rating to a “market perform” rating in a report on Monday, March 11th. HC Wainwright reiterated a “buy” rating and issued a $8.00 target price on shares of Amylyx Pharmaceuticals in a research note on Monday. Mizuho decreased their price target on Amylyx Pharmaceuticals from $4.00 to $3.00 and set a “neutral” rating on the stock in a research report on Tuesday, May 14th. Finally, Leerink Partnrs downgraded Amylyx Pharmaceuticals from an “outperform” rating to a “market perform” rating in a research report on Monday, March 11th. Six investment analysts have rated the stock with a hold rating and two have assigned a buy rating to the company’s stock. According to MarketBeat.com, the company currently has a consensus rating of “Hold” and a consensus price target of $24.80.

Amylyx Pharmaceuticals Company Profile

Amylyx Pharmaceuticals, Inc, a commercial-stage biotechnology company, engages in the discovery and development of treatment for amyotrophic lateral sclerosis (ALS) and neurodegenerative diseases. The company's products include RELYVRIO, a dual UPR-Bax apoptosis inhibitor composed of sodium phenylbutyrate and taurursodiol for the treatment of ALS in adults in the United States and marketed as ALBRIOZA for the treatment of ALS in Canada.